DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and biomarkers

C. F. Lippa, J. E. Duda, M. Grossman, H. I. Hurtig, D. Aarsland, Bradley F Boeve, D. J. Brooks, Dennis W Dickson, B. Dubois, M. Emre, S. Fahn, J. M. Farmer, D. Galasko, J. E. Galvin, C. G. Goetz, J. H. Growdon, K. A. Gwinn-Hardy, J. Hardy, P. Heutink, T. IwatsuboK. Kosaka, V. M Y Lee, J. B. Leverenz, E. Masliah, I. G. McKeith, R. L. Nussbaum, C. W. Olanow, B. M. Ravina, A. B. Singleton, C. M. Tanner, J. Q. Trojanowski, Zbigniew K Wszolek

Research output: Contribution to journalArticle

381 Citations (Scopus)

Abstract

For more than a decade, researchers have refined criteria for the diagnosis of dementia with Lewy bodies (DLB) and at the same time have recognized that cognitive impairment and dementia occur commonly in patients with Parkinson disease (PD). This article addresses the relationship between DLB, PD, and PD with dementia (PDD). The authors agreed to endorse "Lewy body disorders" as the umbrella term for PD, PDD, and DLB, to promote the continued practical use of these three clinical terms, and to encourage efforts at drug discovery that target the mechanisms of neurodegeneration shared by these disorders of α-synuclein metabolism. We concluded that the differing temporal sequence of symptoms and clinical features of PDD and DLB justify distinguishing these disorders. However, a single Lewy body disorder model was deemed more useful for studying disease pathogenesis because abnormal neuronal α-synuclein inclusions are the defining pathologic process common to both PDD and DLB. There was consensus that improved understanding of the pathobiology of α-synuclein should be a major focus of efforts to develop new disease-modifying therapies for these disorders. The group agreed on four important priorities: 1) continued communication between experts who specialize in PDD or DLB; 2) initiation of prospective validation studies with autopsy confirmation of DLB and PDD; 3) development of practical biomarkers for α-synuclein pathologies; 4) accelerated efforts to find more effective treatments for these diseases.

Original languageEnglish (US)
Pages (from-to)812-819
Number of pages8
JournalNeurology
Volume68
Issue number11
DOIs
StatePublished - Mar 2007

Fingerprint

Lewy Body Disease
Molecular Pathology
Dementia
Synucleins
Biomarkers
Parkinson Disease
Lewy Bodies
Therapeutics
Validation Studies
Pathologic Processes
Drug Discovery
Autopsy
Consensus
Communication
Research Personnel
Prospective Studies
Pathology

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

DLB and PDD boundary issues : Diagnosis, treatment, molecular pathology, and biomarkers. / Lippa, C. F.; Duda, J. E.; Grossman, M.; Hurtig, H. I.; Aarsland, D.; Boeve, Bradley F; Brooks, D. J.; Dickson, Dennis W; Dubois, B.; Emre, M.; Fahn, S.; Farmer, J. M.; Galasko, D.; Galvin, J. E.; Goetz, C. G.; Growdon, J. H.; Gwinn-Hardy, K. A.; Hardy, J.; Heutink, P.; Iwatsubo, T.; Kosaka, K.; Lee, V. M Y; Leverenz, J. B.; Masliah, E.; McKeith, I. G.; Nussbaum, R. L.; Olanow, C. W.; Ravina, B. M.; Singleton, A. B.; Tanner, C. M.; Trojanowski, J. Q.; Wszolek, Zbigniew K.

In: Neurology, Vol. 68, No. 11, 03.2007, p. 812-819.

Research output: Contribution to journalArticle

Lippa, CF, Duda, JE, Grossman, M, Hurtig, HI, Aarsland, D, Boeve, BF, Brooks, DJ, Dickson, DW, Dubois, B, Emre, M, Fahn, S, Farmer, JM, Galasko, D, Galvin, JE, Goetz, CG, Growdon, JH, Gwinn-Hardy, KA, Hardy, J, Heutink, P, Iwatsubo, T, Kosaka, K, Lee, VMY, Leverenz, JB, Masliah, E, McKeith, IG, Nussbaum, RL, Olanow, CW, Ravina, BM, Singleton, AB, Tanner, CM, Trojanowski, JQ & Wszolek, ZK 2007, 'DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and biomarkers', Neurology, vol. 68, no. 11, pp. 812-819. https://doi.org/10.1212/01.wnl.0000256715.13907.d3
Lippa, C. F. ; Duda, J. E. ; Grossman, M. ; Hurtig, H. I. ; Aarsland, D. ; Boeve, Bradley F ; Brooks, D. J. ; Dickson, Dennis W ; Dubois, B. ; Emre, M. ; Fahn, S. ; Farmer, J. M. ; Galasko, D. ; Galvin, J. E. ; Goetz, C. G. ; Growdon, J. H. ; Gwinn-Hardy, K. A. ; Hardy, J. ; Heutink, P. ; Iwatsubo, T. ; Kosaka, K. ; Lee, V. M Y ; Leverenz, J. B. ; Masliah, E. ; McKeith, I. G. ; Nussbaum, R. L. ; Olanow, C. W. ; Ravina, B. M. ; Singleton, A. B. ; Tanner, C. M. ; Trojanowski, J. Q. ; Wszolek, Zbigniew K. / DLB and PDD boundary issues : Diagnosis, treatment, molecular pathology, and biomarkers. In: Neurology. 2007 ; Vol. 68, No. 11. pp. 812-819.
@article{b9258934061045e3b020039dcf37f3b9,
title = "DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and biomarkers",
abstract = "For more than a decade, researchers have refined criteria for the diagnosis of dementia with Lewy bodies (DLB) and at the same time have recognized that cognitive impairment and dementia occur commonly in patients with Parkinson disease (PD). This article addresses the relationship between DLB, PD, and PD with dementia (PDD). The authors agreed to endorse {"}Lewy body disorders{"} as the umbrella term for PD, PDD, and DLB, to promote the continued practical use of these three clinical terms, and to encourage efforts at drug discovery that target the mechanisms of neurodegeneration shared by these disorders of α-synuclein metabolism. We concluded that the differing temporal sequence of symptoms and clinical features of PDD and DLB justify distinguishing these disorders. However, a single Lewy body disorder model was deemed more useful for studying disease pathogenesis because abnormal neuronal α-synuclein inclusions are the defining pathologic process common to both PDD and DLB. There was consensus that improved understanding of the pathobiology of α-synuclein should be a major focus of efforts to develop new disease-modifying therapies for these disorders. The group agreed on four important priorities: 1) continued communication between experts who specialize in PDD or DLB; 2) initiation of prospective validation studies with autopsy confirmation of DLB and PDD; 3) development of practical biomarkers for α-synuclein pathologies; 4) accelerated efforts to find more effective treatments for these diseases.",
author = "Lippa, {C. F.} and Duda, {J. E.} and M. Grossman and Hurtig, {H. I.} and D. Aarsland and Boeve, {Bradley F} and Brooks, {D. J.} and Dickson, {Dennis W} and B. Dubois and M. Emre and S. Fahn and Farmer, {J. M.} and D. Galasko and Galvin, {J. E.} and Goetz, {C. G.} and Growdon, {J. H.} and Gwinn-Hardy, {K. A.} and J. Hardy and P. Heutink and T. Iwatsubo and K. Kosaka and Lee, {V. M Y} and Leverenz, {J. B.} and E. Masliah and McKeith, {I. G.} and Nussbaum, {R. L.} and Olanow, {C. W.} and Ravina, {B. M.} and Singleton, {A. B.} and Tanner, {C. M.} and Trojanowski, {J. Q.} and Wszolek, {Zbigniew K}",
year = "2007",
month = "3",
doi = "10.1212/01.wnl.0000256715.13907.d3",
language = "English (US)",
volume = "68",
pages = "812--819",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - DLB and PDD boundary issues

T2 - Diagnosis, treatment, molecular pathology, and biomarkers

AU - Lippa, C. F.

AU - Duda, J. E.

AU - Grossman, M.

AU - Hurtig, H. I.

AU - Aarsland, D.

AU - Boeve, Bradley F

AU - Brooks, D. J.

AU - Dickson, Dennis W

AU - Dubois, B.

AU - Emre, M.

AU - Fahn, S.

AU - Farmer, J. M.

AU - Galasko, D.

AU - Galvin, J. E.

AU - Goetz, C. G.

AU - Growdon, J. H.

AU - Gwinn-Hardy, K. A.

AU - Hardy, J.

AU - Heutink, P.

AU - Iwatsubo, T.

AU - Kosaka, K.

AU - Lee, V. M Y

AU - Leverenz, J. B.

AU - Masliah, E.

AU - McKeith, I. G.

AU - Nussbaum, R. L.

AU - Olanow, C. W.

AU - Ravina, B. M.

AU - Singleton, A. B.

AU - Tanner, C. M.

AU - Trojanowski, J. Q.

AU - Wszolek, Zbigniew K

PY - 2007/3

Y1 - 2007/3

N2 - For more than a decade, researchers have refined criteria for the diagnosis of dementia with Lewy bodies (DLB) and at the same time have recognized that cognitive impairment and dementia occur commonly in patients with Parkinson disease (PD). This article addresses the relationship between DLB, PD, and PD with dementia (PDD). The authors agreed to endorse "Lewy body disorders" as the umbrella term for PD, PDD, and DLB, to promote the continued practical use of these three clinical terms, and to encourage efforts at drug discovery that target the mechanisms of neurodegeneration shared by these disorders of α-synuclein metabolism. We concluded that the differing temporal sequence of symptoms and clinical features of PDD and DLB justify distinguishing these disorders. However, a single Lewy body disorder model was deemed more useful for studying disease pathogenesis because abnormal neuronal α-synuclein inclusions are the defining pathologic process common to both PDD and DLB. There was consensus that improved understanding of the pathobiology of α-synuclein should be a major focus of efforts to develop new disease-modifying therapies for these disorders. The group agreed on four important priorities: 1) continued communication between experts who specialize in PDD or DLB; 2) initiation of prospective validation studies with autopsy confirmation of DLB and PDD; 3) development of practical biomarkers for α-synuclein pathologies; 4) accelerated efforts to find more effective treatments for these diseases.

AB - For more than a decade, researchers have refined criteria for the diagnosis of dementia with Lewy bodies (DLB) and at the same time have recognized that cognitive impairment and dementia occur commonly in patients with Parkinson disease (PD). This article addresses the relationship between DLB, PD, and PD with dementia (PDD). The authors agreed to endorse "Lewy body disorders" as the umbrella term for PD, PDD, and DLB, to promote the continued practical use of these three clinical terms, and to encourage efforts at drug discovery that target the mechanisms of neurodegeneration shared by these disorders of α-synuclein metabolism. We concluded that the differing temporal sequence of symptoms and clinical features of PDD and DLB justify distinguishing these disorders. However, a single Lewy body disorder model was deemed more useful for studying disease pathogenesis because abnormal neuronal α-synuclein inclusions are the defining pathologic process common to both PDD and DLB. There was consensus that improved understanding of the pathobiology of α-synuclein should be a major focus of efforts to develop new disease-modifying therapies for these disorders. The group agreed on four important priorities: 1) continued communication between experts who specialize in PDD or DLB; 2) initiation of prospective validation studies with autopsy confirmation of DLB and PDD; 3) development of practical biomarkers for α-synuclein pathologies; 4) accelerated efforts to find more effective treatments for these diseases.

UR - http://www.scopus.com/inward/record.url?scp=34047223232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047223232&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000256715.13907.d3

DO - 10.1212/01.wnl.0000256715.13907.d3

M3 - Article

C2 - 17353469

AN - SCOPUS:34047223232

VL - 68

SP - 812

EP - 819

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 11

ER -